The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort

Un Jung Kang, Jennifer G. Goldman, Roy N. Alcalay, Tao Xie, Paul Tuite, Claire Henchcliffe, Penelope Hogarth, Amy W. Amara, Samuel Frank, Alice Rudolph, Cynthia Casaceli, Howard Andrews, Katrina Gwinn, Margaret Sutherland, Catherine Kopil, Lona Vincent, Mark Frasier

Research output: Contribution to journalArticle

23 Scopus citations

Abstract

Background: Identifying PD-specific biomarkers in biofluids will greatly aid in diagnosis, monitoring progression, and therapeutic interventions. PD biomarkers have been limited by poor discriminatory power, partly driven by heterogeneity of the disease, variability of collection protocols, and focus on de novo, unmedicated patients. Thus, a platform for biomarker discovery and validation in well-characterized, clinically typical, moderate to advanced PD cohorts is critically needed. Methods: BioFIND (Fox Investigation for New Discovery of Biomarkers in Parkinson's Disease) is a cross-sectional, multicenter biomarker study that established a repository of clinical data, blood, DNA, RNA, CSF, saliva, and urine samples from 118 moderate to advanced PD and 88 healthy control subjects. Inclusion criteria were designed to maximize diagnostic specificity by selecting participants with clinically typical PD symptoms, and clinical data and biospecimen collection utilized standardized procedures to minimize variability across sites. Results: We present the study methodology and data on the cohort's clinical characteristics. Motor scores and biospecimen samples including plasma are available for practically defined off and on states and thus enable testing the effects of PD medications on biomarkers. Other biospecimens are available from off state PD assessments and from controls. Conclusion: Our cohort provides a valuable resource for biomarker discovery and validation in PD. Clinical data and biospecimens, available through The Michael J. Fox Foundation for Parkinson's Research and the National Institute of Neurological Disorders and Stroke, can serve as a platform for discovering biomarkers in clinically typical PD and comparisons across PD's broad and heterogeneous spectrum.

Original languageEnglish (US)
Pages (from-to)924-932
Number of pages9
JournalMovement Disorders
Volume31
Issue number6
DOIs
StatePublished - Jun 1 2016

Keywords

  • Biomarkers
  • Cerebrospinal fluid
  • DNA
  • Plasma
  • RNA
  • Saliva
  • Urine

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort'. Together they form a unique fingerprint.

  • Cite this

    Kang, U. J., Goldman, J. G., Alcalay, R. N., Xie, T., Tuite, P., Henchcliffe, C., Hogarth, P., Amara, A. W., Frank, S., Rudolph, A., Casaceli, C., Andrews, H., Gwinn, K., Sutherland, M., Kopil, C., Vincent, L., & Frasier, M. (2016). The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort. Movement Disorders, 31(6), 924-932. https://doi.org/10.1002/mds.26613